Utilize este identificador para referenciar este registo: https://hdl.handle.net/10216/153769
Registo completo
Campo DCValorIdioma
dc.creatorSharifi-Rad, J
dc.creatorQuispe, C
dc.creatorZam, W
dc.creatorKumar, M
dc.creatorCardoso, SM
dc.creatorPereira, OR
dc.creatorAdemiluyi, AO
dc.creatorAdeleke, O
dc.creatorMoreira, AC
dc.creatorŽivkovic, J
dc.creatorNoriega, F
dc.creatorAyatollahi, SA
dc.creatorKobarfard, F
dc.creatorFaizi, M
dc.creatorMartorell, M
dc.creatorMartins, N
dc.creatorButnariu, M
dc.creatorBagiu, IC
dc.creatorBagiu, RV
dc.creatorAlshehri, MM
dc.creatorCho, WC
dc.date.accessioned2023-11-08T09:57:44Z-
dc.date.available2023-11-08T09:57:44Z-
dc.date.issued2021
dc.identifier.issn1942-0900
dc.identifier.urihttps://hdl.handle.net/10216/153769-
dc.description.abstractCardiovascular diseases (CVD) are one of the main causes of mortality in the world. The development of these diseases has a specific factor-alteration in blood platelet activation. It has been shown that phenolic compounds have antiplatelet aggregation abilities and a positive impact in the management of CVD, exerting prominent antioxidant, anti-inflammatory, antitumor, cardioprotective, antihyperglycemic, and antimicrobial effects. Thus, this review is intended to address the antiplatelet activity of phenolic compounds with special emphasis in preventing CVD, along with the mechanisms of action through which they are able to prevent and treat CVD. In vitro and in vivo studies have shown beneficial effects of phenolic compound-rich plant extracts and isolated compounds against CVD, despite that the scientific literature available on the antiplatelet aggregation ability of phenolic compounds in vivo is scarce. Thus, despite the current advances, further studies are needed to confirm the cardioprotective potential of phenolic compounds towards their use alone or in combination with conventional drugs for effective therapeutic interventions.
dc.description.sponsorshipN.C.-M. acknowledges the Portuguese Foundation for Science and Technology under the Horizon 2020 Program (PTDC/PSI-GER/28076/2017).
dc.language.isoeng
dc.publisherHindawi
dc.relationinfo:eu-repo/grantAgreement/FCT/3599-PPCDT/PTDC%2FPSI-GER%2F28076%2F2017/PT
dc.relation.ispartofOxidative Medicine and Cellular Longevity, vol.2021:2195902
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.meshAnimals
dc.subject.meshCardiovascular Diseases / drug therapy
dc.subject.meshCardiovascular Diseases / metabolism
dc.subject.meshHumans
dc.subject.meshPhenols / chemistry
dc.subject.meshPhenols / therapeutic use
dc.subject.meshPhytochemicals / chemistry
dc.subject.meshPhytochemicals / therapeutic use
dc.subject.meshPlatelet Aggregation / drug effects
dc.subject.meshPlatelet Aggregation Inhibitors / chemistry
dc.subject.meshPlatelet Aggregation Inhibitors / therapeutic use
dc.titlePhenolic Bioactives as Antiplatelet Aggregation Factors: The Pivotal Ingredients in Maintaining Cardiovascular Health
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde
dc.identifier.doi10.1155/2021/2195902
dc.relation.publisherversionhttps://www.hindawi.com/journals/omcl/2021/2195902/
Aparece nas coleções:I3S - Artigo em Revista Científica Internacional

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
10.1155-2021-2195902.pdf1.67 MBAdobe PDFThumbnail
Ver/Abrir


Este registo está protegido por Licença Creative Commons Creative Commons